AHRQ Releases New Guides on Coronary Heart Disease
Documents Summarize Risks, Benefits of ARBs, ACEIs
By News Staff
The Effective Health Care Program of the Agency for Healthcare Research and Quality, or AHRQ, has released summary guides for clinicians and consumers that discuss adjunctive therapy options for patients with stable coronary heart disease.
The clinician guide (2-page PDF; About PDFs) summarizes the current clinical evidence regarding augmenting standard medical therapy for patients with stable ischemic heart disease with an angiotensin-converting enzyme inhibitor, or ACEI, and/or an angiotensin-II receptor blocker, or ARB.
The guides are based on information from a comparative effectiveness review (170-page PDF; About PDFs) prepared last year by the University of Connecticut/Hartford Hospital Evidence-based Practice Center.
The "Clinical Bottom Line" section of the clinician guide lists the following findings:
The guides are based on information from a comparative effectiveness review (170-page PDF; About PDFs) prepared last year by the University of Connecticut/Hartford Hospital Evidence-based Practice Center.
The "Clinical Bottom Line" section of the clinician guide lists the following findings:
- Adding an ACEI to standard treatment reduces total mortality, as well as the incidences of nonfatal myocardial infarction, heart failure-related hospitalization and revascularization. However, the addition of an ACEI also increases the risk of syncope, cough and hyperkalemia.
- Adding an ARB to standard treatment for patients who cannot tolerate ACEIs reduces the combined end points of cardiovascular mortality, nonfatal myocardial infarction and stroke, but it increases the risk of hyperkalemia.
- Adding both an ACEI and an ARB to standard treatment provides no additional clinical benefit compared with adding an ACEI alone, and it increases the risk of hypotension, sudden fainting and renal impairment.
- Adding an ACEI or an ARB to standard treatment in a patient who is soon to undergo a revascularization procedure provides no additional clinical benefit compared with standard therapy alone and increases the risk of subsequent revascularizations and hypotension.
These potential benefits and harms are listed with level-of-confidence ratings in the guide.
The consumer guide (7-page PDF; About PDFs) provides plain-language information about stable coronary heart disease and helps patients understand the benefits and risks of these medications.
Print copies of the guides can be obtained by sending an e-mail to AHRQ or by calling the AHRQ Publications Clearinghouse at (800) 358-9295.
The consumer guide (7-page PDF; About PDFs) provides plain-language information about stable coronary heart disease and helps patients understand the benefits and risks of these medications.
Print copies of the guides can be obtained by sending an e-mail to AHRQ or by calling the AHRQ Publications Clearinghouse at (800) 358-9295.
Related ANN Coverage
AHRQ Releases New Clinician, Consumer Guides on Treating Hypercholesterolemia, Reducing Breast Cancer Risk
(4/27/2010)
AHRQ Guides Help Patients, Physicians Navigate Treatment Options for Gestational Diabetes
(9/8/2009)
AHRQ Publishes New Guide on Osteoporosis Fracture Prevention Treatments
(9/3/2008)
More From AAFP
A-E: Recommendations for Clinical Preventive Services (Scroll down to the "Cardiovascular Disease" entries)
AHRQ Releases New Clinician, Consumer Guides on Treating Hypercholesterolemia, Reducing Breast Cancer Risk
(4/27/2010)
AHRQ Guides Help Patients, Physicians Navigate Treatment Options for Gestational Diabetes
(9/8/2009)
AHRQ Publishes New Guide on Osteoporosis Fracture Prevention Treatments
(9/3/2008)
More From AAFP
A-E: Recommendations for Clinical Preventive Services (Scroll down to the "Cardiovascular Disease" entries)
